IPHA — Innate Pharma S.A.

Innate Pharma Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash position as of March 31, 2026: €25.4 million.
• Partnership agreements with AstraZeneca for monalizumab valued at up to $1.275 billion in milestones, with $450 million received to date.
• IPH5201 partnership worth up to $85 million in milestones, with $60 million received so far.
• Potential for significant non-dilutive cash flow through future milestones, royalties, and profit-sharing arrangements.

2. Strategic Updates and Business Highlights:

• Lacutamab:

  • FDA clearance received for the TELLOMAT-3 Phase III trial in cutaneous T-cell lymphoma (CTCL), expected to initiate in H2 2026.
  • Breakthrough therapy designation for relapsed or refractory Sézary syndrome.
  • Positive Phase II TELLOMAK study results indicate durable activity and quality of life improvements.

• IPH4502:

  • Ongoing Phase I study in advanced solid tumors shows preliminary antitumor activity, particularly in urothelial cancer.
  • Positioned as a differentiated Nectin-4 ADC, potentially addressing unmet needs in bladder cancer and other solid tumors.

• Monalizumab:

  • PACIFIC-9 Phase III study in non-small cell lung cancer (NSCLC) has completed enrollment, with data expected in H2 2026.
  • Partnership with AstraZeneca continues to represent a significant source of future value.

3. Forward Guidance and Outlook:

• Anticipated milestones include:
  • Initiation of the TELLOMAT-3 Phase III study for lacutamab in H2 2026.
  • Continued maturation of clinical data for IPH4502, with updates expected at medical conferences later in the year.
  • Results from the PACIFIC-9 study expected in H2 2026.
• Confidence in securing a partnership or financing for lacutamab before Q3 2026.

4. Challenges and Points of Concern:

• Regulatory and Market Risks: While lacutamab has received several designations, the successful execution of the TELLOMAT-3 trial remains critical.
• Competition: Concerns about competitive pressures from other ADCs, particularly in the Nectin-4 space, were raised, especially with Lilly's product in Phase I and other companies deprioritizing their assets.
• Dependency on Partnerships: The reliance on AstraZeneca for funding and collaboration raises concerns about cash obligations and the potential need for further financing.

5. Notable Q&A Insights:

• Lacutamab Partnerships: Management expressed confidence in finalizing a partnership or financing deal for lacutamab soon, with discussions reportedly advanced.
• IPH4502 Development: Additional details on the drug's profile and potential indications outside bladder cancer are expected to be revealed at upcoming clinical conferences.
• Monalizumab's Efficacy: Questions regarding the efficacy of the MATIS trial indicated that while results are promising, further validation is needed to confirm the drug's potential in the neoadjuvant setting.
• Market Positioning: The company is optimistic about IPH4502's ability to fill therapeutic gaps in bladder cancer treatment, particularly for patients who have progressed after existing therapies.

Overall, Innate Pharma is focused on advancing its key assets while navigating competitive pressures and ensuring adequate funding for its clinical programs.